Illumina, Inc. v. Natera, Inc.

On August 16, 2018, Natera, Inc. (“Defendant”) filed an Answer with Counterclaims against Illumina, Inc. (“Plaintiff”).  In the Answer, the Defendant denies all of the infringement claims being asserted against them, namely, that the Defendant is infringing U.S. Patent No. 9,493,831, which is drawn to a method and kit for performing PCR to detect fetal aneuploidy.  The Defendant further asserts, in the Answer, that the Plaintiff is infringing U.S. Patent No. 8,682,592 (“the ‘592 Patent”), which is assigned to the Defendant, and is drawn to a system and method of determining genetic data from target individuals.  The Defendant is asserting that the Plaintiff is infringing the ‘592 Patent by performing their prenatal tests, including the Verifi® test of the Plaintiff.  The case remains pending and is captioned 3-18-cv-01662.

By:  Jacqueline A. DiRamio

View Attachment (PDF)